Better biomarker signatures change patient lives. #TissuePhenomics: unique tissue signatures that accelerate cancer breakthroughs.

Munich, Germany
Joined December 2009
Do you want to understand how #artificialintelligence can support #patient profiling in #precisiononcology. Download your free chapter of Tissue Phenomics here! bit.ly/2UwGZqQ
1
Why #AI-powered Biomarker Analysis is the Future of #Cancer Immune Profiling. Checkpoint inhibitors in #immunotherapy are a major medical breakthrough but scientists & doctors must use AI-powered biomarker analysis for better #immuneprofiling. bit.ly/30L9Udd
1
Here's Dr. Andreas Spitzmueller yesterday at #WCLC2019 with his poster: Tumor Proliferation Associated with #Tumor Immunological Status: Study of NSCLC Using Multiplex Immunofluorescence. Thanks to everyone who came by yesterday! wclc2019.iaslc.org/
1
Do you want to understand how #artificialintelligence can support #patient profiling in #precisiononcology. Download your free chapter of Tissue Phenomics here! bit.ly/2ZMu0Gw
1
Please join us at @HISTALIM -Multiplex Histopathology Annual Meeting- in Montpellier Sept.12, 2019. Dr. Florian Leiss & Dr. Ana Hidalgo-Sastre will discuss multiplex digital imaging and patient #immuneprofiling! #immunotherapy bit.ly/30T8LAg
See you at @IASLC #WCLC19 in Barcelona this weekend! Please join Dr. Andreas Spitzmueller for his poster presentation: Tumor Proliferation Associated with #Tumor Immunological Status: Study of NSCLC Using Multiplex Immunofluorescence. bit.ly/2UBSc9M
Have you read our latest newsletter yet? Don't miss out - find out about our FREE upcoming events before #SITC19, #ESMO19, and meet us at World CB & CDx! Read it here: bit.ly/30S6ipz #immunotherapy #immunoOncology #biomarkers
See you at @IASLC #WCLC19 in Barcelona this weekend! Please join Dr. Andreas Spitzmueller for his poster presentation: Tumor Proliferation Associated with #Tumor Immunological Status: Study of NSCLC Using Multiplex Immunofluorescence. bit.ly/2ZIYJo6
1
#FridayFacts #immunotherapy #DYK- Did you know: mIHC/IF is the most accurate approach in predicting response to anti-PD-1/PD-L1 therapy? Check out this meta-study to compare here: jamanetwork.com/journals/jam…
During #SITC2019's Workshop on Intratumoral Immunomodulation, the current status of intratumoral immunomodulation will be presented and future directions for the field will be discussed, along with implications for immunotherapy treatments. sitcancer.org/2019/program/p…
3
4
This Post is from an account that no longer exists. Learn more
The potential and barely tested landscape of combination immunotherapies - birds eye view by Marc Ernstoff, more to come on this from @JaniceM10’s concluding talk on the future of immunotherapy @sitcancer #ACI2019 #CLEedition
Attending @HISTALIM -Multiplex Histopathology Annual Meeting- in Montpellier Sept.12, 2019? Please join Dr. Florian Leiss & Dr. Ana Hidalgo-Sastre, who will discuss multiplex digital imaging and patient #immuneprofiling! #immunotherapy bit.ly/2ZFcfsQ
1
1
Have you read our latest newsletter yet? Don't miss out - find out about our FREE upcoming events before #SITC19, #ESMO19, and meet us at World CB & CDx! Read it here: bit.ly/30RKkmR #immunotherapy #immunoOncology #biomarkers
Why #AI-powered Biomarker Analysis is the Future of #Cancer Immune Profiling. Checkpoint inhibitors in #immunotherapy are a major medical breakthrough but scientists & doctors must use AI-powered biomarker analysis for better #immuneprofiling. bit.ly/2ZEpOsy